ArticleOncotarget2016

Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.

Marco A De Velasco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.